Daily biotech intelligence: FDA actions, drug recalls, and recent research.
ATORVASTATIN CALCIUM — Approved Sponsor: SCIEGEN PHARMS · Application type: ORIG · Date: 20160519 · Priority: STANDARD
Unknown — Approved Sponsor: APOTEX INC · Application type: ORIG · Date: 20260430
CRESTOR (ROSUVASTATIN) — Approved Sponsor: ASTRAZENECA · Application type: SUPPL · Date: 20240731 · Priority: STANDARD
TRANEXAMIC ACID — Approved Sponsor: EUGIA PHARMA · Application type: SUPPL · Date: 20201210 · Priority: STANDARD
Unknown — Tentative Approval Sponsor: QILU PHARM CO LTD · Application type: ORIG · Date: 20260429 · Priority: STANDARD
NGENLA (SOMATROGON-GHLA) — Approved Sponsor: PFIZER IRELAND PHARMACEUTICALS · Application type: ORIG · Date: 20230627 · Priority: STANDARD
Unknown — Tentative Approval Sponsor: HETERO LABS LIMITED · Application type: ORIG · Date: 20260429 · Priority: STANDARD
Unknown — Approved Sponsor: HUMANWELL · Application type: ORIG · Date: 20260429 · Priority: STANDARD
CARBAMAZEPINE — Approved Sponsor: ZYDUS PHARMS · Application type: SUPPL · Date: 20260429 · Priority: STANDARD
PAVBLU (AFLIBERCEPT-AYYH) — Approved Sponsor: AMGEN INC · Application type: SUPPL · Date: 20260428 · Priority: N/A
The Harvard Drug Group LLC [Class II] — 20260429 Product: Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose blister cards) per Reason: Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.
B BRAUN MEDICAL INC [Class II] — 20260429 Product: DEXTROSE INJECTION USP, 70%, 2000 mL bags, Rx only, Sterile, B. Braun Medical Inc., Bethlehem, PA 18 Reason: Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
Leading Pharma, LLC [Class II] — 20260429 Product: Furosemide Tablets, USP, 80 mg, 100 Tablets bottles, Rx only, Manufactured by: Leading Pharma, LLC, Reason: CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Premier Dental Products Co [Class III] — 20260429 Product: Premier, Monsel's, Ferric Subsulfate Solution, 8 mL bottles, Rx only, Manufacturer: Premier Medical Reason: Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (202
B BRAUN MEDICAL INC [Class II] — 20260429 Product: LACTATED RINGER'S IRRIGATION, 3000 mL bags, Sterile, Ex only, B. Braun Medical Inc., Bethlehem, PA 1 Reason: Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
Shikhar Shukla · 2026-05-04 · cs.LG · cs.AI
Speculative decoding accelerates large language model (LLM) inference by using a small draft model to propose candidate tokens that a larger target model verifies. A critical hyperparameter in this process is the speculation length~$γ$, which determines how many tokens the draft model proposes per step. Nearly all existing systems use a fixed~$γ$ (
Bogdan Oancea · 2026-05-04 · cs.LG
Ensuring the coherence of regional socio-economic statistics is a central task for national statistical institutes. Traditional validation tools, such as range edits, ratio checks, or univariate outlier detection, are effective for identifying extreme values in individual series but are less suited for detecting unusual combinations of indicators i
Haizhou Wen, Elham Kiyani, Gang Li · 2026-05-04 · physics.comp-ph · cs.LG
Composite materials exhibit strongly hierarchical and anisotropic properties governed by coupled mechanisms spanning constituents, plies, laminates, structures, and manufacturing history. This intrinsic complexity makes predictive modeling of composites expensive, because repeated experiments and high-fidelity simulations are needed to cover large
Lingxiao Kong, Cong Yang, Oya Deniz Beyan · 2026-05-04 · cs.LG · cs.AI
Despite significant advances in Reinforcement Learning (RL), model performance remains highly sensitive to algorithm and hyperparameter configurations, while generalization gaps across environments complicate real-world deployment. Although prior work has studied RL generalization, the relative contribution of specific configurations to the general
Mohamad Khajezade, Fatemeh H. Fard, Mohamed Sami Shehata · 2026-05-04 · cs.AI · cs.LG
Cross-language code clone detection (X-CCD) is challenging because semantically equivalent programs written in different languages often share little surface similarity. Although large language models (LLMs) have shown promise for semantic clone detection, their use as black-box systems raises concerns about cost, reproducibility, privacy, and unre
Arian Eamaz, Farhang Yeganegi, Mojtaba Soltanalian · 2026-05-04 · cs.LG
Understanding whether deep neural networks are effectively optimized remains challenging, as training occurs in highly nonconvex landscapes and standard metrics provide limited visibility into layer-wise learning quality. This challenge is particularly acute for transformer-based language models, where training is expensive, models are often reused
Xinhui Xiong, Bin Gao, P. -A. Absil · 2026-05-04 · math.OC · cs.AI
Retraction-free approaches offer attractive low-cost alternatives to Riemannian methods on the Stiefel manifold, but they are often first-order, which may limit the efficiency under high-accuracy requirements. To this end, we propose a second-order method landing on the Stiefel manifold without invoking retractions, which is proved to enjoy local q
Sushovan Majhi, Atish Mitra, Žiga Virk · 2026-05-04 · cs.LG · math.AT
We introduce PLACE (Persistence-Landmark Analytic Classification Engine), a closed-form pipeline for classifying point clouds and graphs through their persistent-homology signatures. Three quantitative guarantees -- a margin-based excess-risk rate, a closed-form descriptor-selection rule, and a per-prediction certificate -- are derived from trainin
STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight (STAT News) A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S. (STAT News) Leaving the WHO means the U.S. lacks access to necessary information about infectious disease.
Opinion: The ‘brain drain’ narrative about health professionals misses half of the story (STAT News) 52 health professionals returned home to 43 countries. Here are the unexpected challenges and opportunities they faced.
STAT+: Johnson & Johnson advances IBD therapy, despite trial miss (STAT News) A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns (STAT News) France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
Opinion: Mifepristone court ruling makes drug development riskier for everyone (STAT News) The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies (STAT News) The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
Researchers urge study of paternal deaths, though a new paper finds fatherhood is protective (STAT News) A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention
STAT+: Pump the brakes on AI, buddy; and deposition deadlock (STAT News) It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
UCB to acquire maker of antibody treatments for autoimmune diseases (STAT News) A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Cytospire hauls in $83M for a new type of T cell engager (BioPharma Dive) The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
Celcuity strengthens case for ASCO-spotlighted breast cancer drug (BioPharma Dive) The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
This briefing is compiled automatically from FDA public APIs (openFDA), arXiv, and industry RSS feeds (STAT News, Fierce Biotech, BioPharma Dive, Nature, Science News). Not investment advice. Verify all data before making any decisions.